RENEO PHARMACEUTICALS INC (RPHM) Stock Price, Quote, News and Overview
NASDAQ:RPHM - Nasdaq - US75974E1038 - Common Stock - Currency: USD
RPHM Quote, Performance and Key Statistics
1.82
+0.09 (+5.2%)
The current stock price of RPHM is 1.82 USD. In the past month the price increased by 27.27%. In the past year, price decreased by -77.97%.
RPHM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RPHM
Company Profile
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 8 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Company Info
RENEO PHARMACEUTICALS INC
18575 Jamboree Road, Suite 275-S
Irvine CALIFORNIA US
Employees: 8
Company Website: https://reneopharma.com/
Phone: 18582830280
RENEO PHARMACEUTICALS INC / RPHM FAQ
What is the stock price of RENEO PHARMACEUTICALS INC today?
The current stock price of RPHM is 1.82 USD. The price increased by 5.2% in the last trading session.
What is the ticker symbol for RENEO PHARMACEUTICALS INC stock?
The exchange symbol of RENEO PHARMACEUTICALS INC is RPHM and it is listed on the Nasdaq exchange.
On which exchange is RPHM stock listed?
RPHM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RENEO PHARMACEUTICALS INC stock?
7 analysts have analysed RPHM and the average price target is 2.3 USD. This implies a price increase of 26.1% is expected in the next year compared to the current price of 1.82. Check the RENEO PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RENEO PHARMACEUTICALS INC worth?
RENEO PHARMACEUTICALS INC (RPHM) has a market capitalization of 24.28M USD. This makes RPHM a Nano Cap stock.
How many employees does RENEO PHARMACEUTICALS INC have?
RENEO PHARMACEUTICALS INC (RPHM) currently has 8 employees.
What are the support and resistance levels for RENEO PHARMACEUTICALS INC (RPHM) stock?
RENEO PHARMACEUTICALS INC (RPHM) has a support level at 1.66 and a resistance level at 1.83. Check the full technical report for a detailed analysis of RPHM support and resistance levels.
Should I buy RENEO PHARMACEUTICALS INC (RPHM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RPHM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RPHM, evaluating the profitability, health, valuation and growth aspects
- RENEO PHARMACEUTICALS INC (RPHM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RENEO PHARMACEUTICALS INC (RPHM) Sales and EPS estimates to see what analysts future expectations are.
- RENEO PHARMACEUTICALS INC (RPHM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RENEO PHARMACEUTICALS INC (RPHM) Insider and Institutional Ownership to learn about the owners and their transactions.
- RENEO PHARMACEUTICALS INC (RPHM) Stock Chart to make your own analysis
- RENEO PHARMACEUTICALS INC (RPHM) Latest news and press-releases to stay up to date.
Does RENEO PHARMACEUTICALS INC (RPHM) stock pay dividends?
RPHM does not pay a dividend.
When does RENEO PHARMACEUTICALS INC (RPHM) report earnings?
RENEO PHARMACEUTICALS INC (RPHM) will report earnings on 2024-11-06, before the market open.
What is the Price/Earnings (PE) ratio of RENEO PHARMACEUTICALS INC (RPHM)?
RENEO PHARMACEUTICALS INC (RPHM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.69).
RPHM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RPHM. When comparing the yearly performance of all stocks, RPHM is a bad performer in the overall market: 89.02% of all stocks are doing better.
RPHM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RPHM. RPHM has a great financial health rating, but its profitability evaluates not so good.
RPHM Financial Highlights
Over the last trailing twelve months RPHM reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS increased by 27.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.83% | ||
| ROE | -73.56% | ||
| Debt/Equity | 0 |
RPHM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to RPHM. The Buy consensus is the average rating of analysts ratings from 7 analysts.